Figure 6: SPM-adjuvanted P6 vaccination decreases SHS-exacerbated pulmonary immune cell infiltration following acute infection.

(A-B) SHS-exposed mice, untreated or treated with AT-RvD1 for 8 consecutive wks before vaccination with P6 ± SPM adjuvant (17-HDHA or AT-RvD1), were given acute pulmonary NTHI challenge 8 wks after the start of vaccination. (C) Total numbers of CD11b⁺Ly6G⁺ neutrophils, (D) CD4⁺IL-17A⁺ T cells and (E) CD4⁺RoRγt⁺ T cells accumulating in the lungs at 4 and 24 h following acute infection were determined by flow cytometry using cell-specific markers as described in the methods section. Gating strategy that was utilized is shown in supplemental Figure 1. (F) Multiple comparisons table with Tukey’s post-hoc comparisons and p values are provided. All treatment groups were assayed at the same time, and data represent results generated from a single experiment using a total of 60 mice (n=5 mice for each treatment at each time point. The results are depicted as geometric mean ± 95% C.I. Statistical significance was determined as described in the methods section (overall p<0.0001 [CD11b⁺Ly6G⁺ neutrophils, CD4⁺IL17A⁺ T cells, CD4⁺Rorgt⁺ T cells, 4 and 24 h] comparing SHS, sham or SHS, P6+vehicle group vs all treatment groups with Tukey’s posttest for multiple comparisons.